Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CP Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Gait Retraining for Children With Cerebral Palsy

NCT04717323
View directory record Official record
Conditions
Cerebral Palsy, Gait Disorders, Neurologic
Interventions
mPAD (or TPAD) Pelvic Assist Device, No Intervention
Device
Lead sponsor
Altec Inc.
Industry
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Natick, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 22, 2026, 12:50 PM EDT
Recruiting No phase listed Observational

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00499317
View directory record Official record
Conditions
Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS), Painful Bladder Syndrome (PBS), Benign Frequency Syndrome (BFS), Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 12:50 PM EDT
Recruiting Not applicable Interventional

Neuromuscular Mechanisms of Specific Trunk Interventions in Children With CP

NCT05805410
View directory record Official record
Conditions
Child Behavior
Interventions
robotic hippotherapy, Conventional physical therapy
Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
4 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jul 22, 2026, 12:50 PM EDT
Terminated Phase 2 Interventional Results available

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

NCT00644878
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Phase 3 Interventional Results available

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

NCT04666259
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
ABL001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
Anchorage, Alaska • Phoenix, Arizona • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 22, 2026, 12:50 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02890381
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID cp ΔM2-2 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jul 22, 2026, 12:50 PM EDT
Suspended Not applicable Interventional

Functional Strength Training and Virtual Reality in Children With CP

NCT04147468
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Virtual Reality, Functional Strength Training
Other
Lead sponsor
Georgia State University
Other
Eligibility
6 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Phase 2 Interventional Results available

Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta

NCT01278303
View directory record Official record
Conditions
Aortic Coarctation
Interventions
Treatment of Aortic Wall Injury
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
19
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jul 22, 2026, 12:50 PM EDT
Completed No phase listed Observational

Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting

NCT07374120
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic-Phase
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 22, 2026, 12:50 PM EDT
Terminated Phase 1 Interventional

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

NCT00585000
View directory record Official record
Conditions
Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Jul 22, 2026, 12:50 PM EDT
Terminated Not applicable Interventional Results available

Impella CP With VA ECMO for Cardiogenic Shock

NCT03431467
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Impella-CP LV Vent
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Phase 2 Interventional

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00042016
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
decitabine (5-aza-2'deoxycytidine)
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
7
States / cities
Duarte, California • Escondido, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Jul 22, 2026, 12:50 PM EDT
Completed No phase listed Observational

EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

NCT07103642
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
3,402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

NCT01254175
View directory record Official record
Conditions
Parainfluenza Virus 3, Human
Interventions
rHPIV3cp45 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Long Beach, California • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Jul 22, 2026, 12:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191
View directory record Official record
Conditions
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Interventions
Asciminib, Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
9
States / cities
Denver, Colorado • Peoria, Illinois • Saint Paul, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Early Phase 1 Interventional

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

NCT02157831
View directory record Official record
Conditions
Solid Tumors
Interventions
CP-870,893
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 22, 2026, 12:50 PM EDT
Recruiting Phase 2 Interventional

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

NCT04838041
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia
Interventions
Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily, Imatinib, Nilotinib, Dasatinib
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Detroit, Michigan • New York, New York • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Not applicable Interventional

FES Assisted Cycling in Children With CP

NCT04688424
View directory record Official record
Conditions
Cerebral Palsy Spastic Diplegia
Interventions
FES, Cycling
Device · Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Jul 22, 2026, 12:50 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

NCT00124748
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic Phase
Interventions
Imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
50
States / cities
Mobile, Alabama • Berkeley, California • Campbell, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jul 22, 2026, 12:50 PM EDT
Not listed Not applicable Interventional

Comparative Evaluation of A-CP HA Kit, Hyaluronic Acid and Placebo for the Treatment of Knee Osteoarthritis

NCT03201614
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
A-CP HA Kit, ArthroVisc 40, Placebo
Device · Drug
Lead sponsor
Regen Lab SA
Industry
Eligibility
50 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 22, 2026, 12:50 PM EDT
Withdrawn No phase listed Observational

Starling/CRRT Observational Study

NCT05729048
View directory record Official record
Conditions
Hemodynamic Monitoring
Interventions
Starling
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)

NCT02862912
View directory record Official record
Conditions
Adverse Reaction to Spinal Anesthetic, Maternal Care for Cervical Incompetence
Interventions
Chloroprocaine, Bupivacaine, Fentanyl, Saline
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jul 22, 2026, 12:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bimanual Training in Children With Hemiplegia

NCT01413594
View directory record Official record
Conditions
Hemiplegia, Cerebral Palsy, Children
Interventions
HABIT
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Months to 16 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jul 22, 2026, 12:50 PM EDT